Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep:59 Suppl 1:S104-S111.
doi: 10.1002/jcph.1478.

Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling

Affiliations
Review

Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling

Youwei Bi et al. J Clin Pharmacol. 2019 Sep.

Abstract

The unique challenges in pediatric drug development require efficient and innovative tools. Model-informed drug development (MIDD) offers many powerful tools that have been frequently applied in pediatric drug development. MIDD refers to the application of quantitative models to integrate and leverage existing knowledge to bridge knowledge gaps and facilitate development and decision-making processes. This article discusses the current practices and visions of applying MIDD in pediatric drug development, regulatory evaluation, and labeling, with detailed examples. The application of MIDD in pediatric drug development can be broadly classified into 3 categories: leveraging knowledge for bridging the gap, dose selection and optimization, and informing clinical trial design. In particular, MIDD can provide evidence for the assumption of exposure-response similarity in bridging existing knowledge from reference to target population, support the dose selection and optimization based on the "exposure-matching" principle in the pediatric population, and increase the efficiency and success rate of pediatric trials. In addition, the role of physiologically based pharmacokinetics in drug-drug interaction in children and adolescents and in utilizing ontogeny data to predict pharmacokinetics in neonates and infants has also been illustrated. Moving forward, MIDD should be incorporated into all pediatric drug development programs at every stage to inform clinical trial design and dose selection, with both its strengths and limitations clearly laid out. The accumulated experience and knowledge of MIDD has and will continue to drive regulatory policy development and refinement, which will ultimately improve the consistency and efficiency of pediatric drug development.

Keywords: dose selection and optimization; informing clinical trial design; leveraging knowledge; model-informed drug development; pediatric drug development; pediatric ontogeny.

PubMed Disclaimer

Similar articles

Cited by

References

    1. US Food and Drug Administration (FDA). Best Pharmaceuticals for Children Act and Pediatric Research Equity Act. Status report to Congress. https://www.fda.gov/media/99184/download. Accessed July 1, 2016.
    1. US Food and Drug Administration (FDA). How to comply with the Pediatric Research Equity Act. https://www.fda.gov/media/72274/download. Accessed September 1, 2005.
    1. Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA. 2012;307:1914-1915.
    1. Lynne P. Yao. Pediatric drug development: moving toward the best pharmaceuticals for children. Pediatric Drug Development Workshop. March 24, 2017. American Course on Drug Development and Regulatory Sciences.
    1. Momper JD, Mulugeta Y, Burckart GJ. Failed pediatric drug development trials. Clin Pharmacol Ther. 2015;98:245-251.

LinkOut - more resources